time of presentation ( Korse et al . 2013 ). In the past decade a promising new treatment modality has been developed for inoperable or metastasized NETs. This peptide receptor radionuclide therapy (PRRT) uses radiolabeled somatostatin analogues. Since
Search Results
Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Richard A Feelders, Eric P Krenning, and Dik J Kwekkeboom
Mintallah Haider, Satya Das, Taymeyah Al-Toubah, Eleonora Pelle, Ghassan El-Haddad, and Jonathan Strosberg
, Remes et al. 2019 ). An emerging class of therapeutics for patients with WD NETs consists of radiolabeled somatostatin analogs (SSA), which fall under the broader therapeutic class of peptide receptor radionuclide therapy (PRRT). PRRT enables the
Tessa Brabander, Julie Nonnekens, and Johannes Hofland
radionuclide therapy (PRRT) ( Kwekkeboom et al. 2005 ). This was successfully implemented for [ 90 Y]Y-DOTA-[Tyr3]octreotide ( 90 Y-DOTATOC) and [ 177 Lu]Lu-DOTA-[Tyr3]octreotate ( 177 Lu-DOTATATE), with the latter radioligand now registered for therapy of
Lisa Bodei, Irvin M Modlin, Markus Luster, Flavio Forrer, Marta Cremonesi, Rodney J Hicks, Samer Ezziddin, Mark Kidd, and Arturo Chiti
Introduction It is now widely accepted that peptide receptor radionuclide therapy (PRRT) is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic (GEP) or
Cecile N Chougnet, Sophie Leboulleux, Caroline Caramella, Jean Lumbroso, Isabelle Borget, Désirée Déandreis, Pierre Duvillard, Dominique Elias, Thierry de Baere, Fritz-Line Vélayoudom-Céphise, Joël Guigay, Michel Ducreux, Martin Schlumberger, and Eric Baudin
tomography (PET)-dedicated tracers ( Ambrosini et al . 2008 , Srirajaskanthan et al . 2010 ) and the use of tracers with higher affinity for sstr ( Krenning et al . 1999 , Carrasquillo & Chen 2010 ). Peptide receptor radionuclide therapy (PRRT) that uses
Wouter T Zandee, Kimberly Kamp, Roxanne C van Adrichem, Richard A Feelders, and Wouter W de Herder
times daily for octreotide subcutaneously, once more improving quality of life for patients ( Rinke et al . 2009 , Caplin et al . 2014 ). Also peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs and tumor
Halfdan Sorbye, Grace Kong, and Simona Grozinsky-Glasberg
Background Peptide receptor radionuclide therapy (PRRT) Peptide receptor radionuclide therapy (PRRT) delivers highly localized radiation by targeting specific peptide receptors on tumor cells ( Hicks et al . 2017 ). This therapy has been
David A Pattison and Rodney J Hicks
in patients deemed otherwise suitable for peptide receptor radionuclide therapy (PRRT). Figure 1 Molecular targets currently utilised for imaging and radionuclide therapy of insulinoma. Adapted from Trends in Endocrinology & Metabolism , Vol
Esben Andreas Carlsen, Nicola Fazio, Dan Granberg, Simona Grozinsky-Glasberg, Hojjat Ahmadzadehfar, Chiara Maria Grana, Wouter T Zandee, Jaroslaw Cwikla, Martin A Walter, Peter Sandor Oturai, Anja Rinke, Andrew Weaver, Andrea Frilling, Sara Gritti, Anne Kirstine Arveschoug, Amichay Meirovitz, Ulrich Knigge, and Halfdan Sorbye
, Yamaguchi et al . 2014 , Heetfeld et al . 2015 , Walter et al . 2017 ). In metastatic GEP NET G1–G2, peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors has been used with excellent results for the last two decades in Europe
Jaap J M Teunissen, Dik J Kwekkeboom, R Valkema, and Eric P Krenning
patients who had inoperable and/or metastasised NETs. Therefore, the first peptide receptor radionuclide therapy (PRRT) was performed with high administered activity of [ 111 In-DTPA 0 ]octreotide ( Krenning et al . 1994 a ). However, besides encouraging
